Correlation Between Innovent Biologics and Inhibrx

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Innovent Biologics and Inhibrx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Innovent Biologics and Inhibrx into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Innovent Biologics and Inhibrx, you can compare the effects of market volatilities on Innovent Biologics and Inhibrx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Innovent Biologics with a short position of Inhibrx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Innovent Biologics and Inhibrx.

Diversification Opportunities for Innovent Biologics and Inhibrx

0.14
  Correlation Coefficient

Average diversification

The 3 months correlation between Innovent and Inhibrx is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Innovent Biologics and Inhibrx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibrx and Innovent Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Innovent Biologics are associated (or correlated) with Inhibrx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibrx has no effect on the direction of Innovent Biologics i.e., Innovent Biologics and Inhibrx go up and down completely randomly.

Pair Corralation between Innovent Biologics and Inhibrx

Assuming the 90 days horizon Innovent Biologics is expected to generate 1.21 times more return on investment than Inhibrx. However, Innovent Biologics is 1.21 times more volatile than Inhibrx. It trades about 0.1 of its potential returns per unit of risk. Inhibrx is currently generating about -0.02 per unit of risk. If you would invest  475.00  in Innovent Biologics on December 30, 2024 and sell it today you would earn a total of  115.00  from holding Innovent Biologics or generate 24.21% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy95.38%
ValuesDaily Returns

Innovent Biologics  vs.  Inhibrx

 Performance 
       Timeline  
Innovent Biologics 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Innovent Biologics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Innovent Biologics reported solid returns over the last few months and may actually be approaching a breakup point.
Inhibrx 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Innovent Biologics and Inhibrx Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Innovent Biologics and Inhibrx

The main advantage of trading using opposite Innovent Biologics and Inhibrx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Innovent Biologics position performs unexpectedly, Inhibrx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibrx will offset losses from the drop in Inhibrx's long position.
The idea behind Innovent Biologics and Inhibrx pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Complementary Tools

Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like